Team ADVITY will be attending CPHI Milan 2026 from October 6–8, 2026, at Fiera Milano, Italy.
CPHI Milan brings together pharmaceutical companies, innovators, service providers, researchers and industry leaders from across the global pharmaceutical ecosystem. ADVITY Research looks forward to connecting with existing partners, prospective clients and industry professionals to discuss opportunities in Bioavailability/Bioequivalence (BA/BE), Early Phase Clinical Development, PK/PD studies, Bioanalytical Services and integrated clinical research solutions.
ADVITY Research is an independent Clinical Research Organization (CRO) in India, providing integrated clinical development services to pharmaceutical and biotechnology companies.
Our Early Phase capabilities include BA/BE studies, Phase I studies, PK/PD studies, clinical endpoint studies, bioanalytical services, biostatistics, data management and medical writing, enabling sponsors to work with an integrated clinical research partner across key stages of their development programs.
At CPHI Milan 2026, our team welcomes discussions with pharmaceutical and biotechnology companies looking for a reliable partner for their upcoming BA/BE and Early Phase development programs.
ADVITY provides Bioavailability and Bioequivalence study services designed to support generic, complex generic and pharmaceutical development programs while meeting applicable global regulatory requirements.
Our BA/BE and Early Phase capabilities include:
Our experience with complex study designs, specialized participant populations and challenging development programs allows us to provide flexible solutions based on the scientific and operational requirements of each study.
Strong bioanalytical capabilities are critical to the successful execution of BA/BE and pharmacokinetic studies.
ADVITY provides bioanalytical support for small and large molecules, supported by advanced analytical platforms including LC-MS/MS and ligand-binding assays such as ELISA.
Our capabilities include method development and validation, pharmacokinetic sample analysis and specialized analytical support for clinical development programs.
By integrating clinical conduct, bioanalysis, data management, biostatistics and medical writing, ADVITY helps sponsors streamline study execution and maintain consistency across the development lifecycle.
ADVITY also provides specialized glucose clamping study services supporting insulin and biosimilar insulin development programs.
Our integrated glucose clamping capabilities cover study design and protocol development, regulatory support, clinical conduct, bioanalysis, data management and biostatistics, providing sponsors with coordinated support for complex insulin development studies.
If you are planning an upcoming BA/BE study, Phase I study, PK/PD program, complex bioequivalence study, bioanalytical project or glucose clamping study, we would be pleased to meet you during CPHI Milan 2026.
Meet Team ADVITY and discover how our scientific expertise, integrated capabilities and flexible approach can support your clinical development programs.
CPHI Milan 2026
Dates: October 6–8, 2026
Venue: Fiera Milano, Italy
To schedule a meeting with our team during CPHI Milan 2026, please contact:
We look forward to connecting with pharmaceutical and biotechnology professionals in Milan and exploring opportunities to collaborate on future BA/BE, Early Phase and clinical development programs.
ADVITY Research — Adding Value with Integrity.
